{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056916","form_type":"8-K","ticker":null,"cik":"0001656634","company_name":"Gritstone bio, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.457361+00:00","generated_at":"2026-06-02T06:12:38.598008+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gritstone reports Q1 cash $52.8M; GRANITE Phase 2 MSS-CRC shows favorable PFS trend (HR 0.82 overall, 0.52 high-risk)","bullets":["Cash, equivalents and marketable securities $52.8M as of March 31, 2024, down from $86.9M at Dec 31, 2023.","Preliminary Phase 2 GRANITE data: PFS hazard ratio 0.82 overall (95% CI 0.34-1.67) and 0.52 in high-risk group (95% CI 0.15-1.38); mature data expected Q3 2024.","Completed public offering in April 2024 for gross proceeds of $32.5M; appointed Stephen Webster to Board.","R&D expenses $33.0M, G&A $8.5M for Q1 2024; collaboration & grant revenue $1.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056916","json":"https://secwatch.observer/filing/0000950170-24-056916.json","markdown":"https://secwatch.observer/filing/0000950170-24-056916.md","text":"https://secwatch.observer/filing/0000950170-24-056916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1656634/000095017024056916/0000950170-24-056916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1656634/000095017024056916/grts-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:12:38.598008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43ebc8f0c76cfa26d2d6fd346b5cf48dffab6129","claim":"Gritstone bio, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Gritstone bio, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1656634/000095017024056916/0000950170-24-056916-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}